Simply Wall St.
High Growth US Tech Stocks To Watch In December 2025
📊
AI Sentiment
Positive
7/10
- Home
- RNXT
RNXT
RenovoRx Inc.
as of 12-05-2025 3:39pm EST
$0.94
$0.01
-1.34%
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Chart Type:
Time Range:
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | MOUNTAIN VIEW |
| Market Cap: | 32.5M | IPO Year: | 2021 |
| Target Price: | $7.75 | AVG Volume (30 days): | 343.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.70 - $1.69 | Next Earning Date: | 11-13-2025 |
| Revenue: | $928,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 2795.35% | Revenue Growth (next year): | 272.69% |
AI-Powered RNXT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 75.68%
75.68%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of RenovoRx Inc. (RNXT)
Agah Ramtin
Buy
Chief Medical Officer
RNXT Nov 24, 2025
Avg Cost/Share
$0.80
Shares
12,000
Total Value
$9,600.00
Owned After
756,460
SEC Form 4
Agah Ramtin
Buy
Chief Medical Officer
RNXT Nov 21, 2025
Avg Cost/Share
$0.80
Shares
10,000
Total Value
$8,000.00
Owned After
756,460
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Agah Ramtin | RNXT | Chief Medical Officer | Nov 24, 2025 | Buy | $0.80 | 12,000 | $9,600.00 | 756,460 | |
| Agah Ramtin | RNXT | Chief Medical Officer | Nov 21, 2025 | Buy | $0.80 | 10,000 | $8,000.00 | 756,460 |
Latest RenovoRx Inc. News
RNXT Breaking Stock News: Dive into RNXT Ticker-Specific Updates for Smart Investing
ACCESS Newswire
iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025
📊
AI Sentiment
Positive
7/10
GlobeNewswire
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th
📊
AI Sentiment
Positive
7/10
Compare RNXT vs Leading Stocks
See how RNXT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RNXT RenovoRx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.